Polycyclic compound and use thereof

By developing polycyclic compounds with excellent proliferation inhibitory activity, the problem of proliferative diseases caused by abnormal YAP/TEAD activity in the prior art is solved, especially cancer, and effective use of the YAP-TEAD signaling pathway is achieved. Inhibiting and anti-tumor effects.

WO2024230104A1PCT designated stage expired Publication Date: 2024-11-14TYK MEDICINES INC
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/130521
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2023-11-08
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The prior art is difficult to effectively regulate and treat proliferative diseases caused by abnormal activity of YAP/TEAD, especially cancers. Hippo pathway disorders are common in a variety of human cancers, and existing treatment methods are limited.

Method used

A structurally novel polycyclic compound with excellent proliferation inhibitory activity and YAP-TEAD inhibitory activity was developed, and the compound was prepared by structural optimization for the prevention and treatment of proliferative diseases, especially cancer.

Benefits of technology

The compound showed significant anti-tumor activity, was able to effectively inhibit the YAP-TEAD signaling pathway, significantly reduced cell proliferation and oncogenic transformation activities, had excellent pharmacokinetic properties and the ability to penetrate the blood-brain barrier, providing new Methods for treating diseases caused by abnormal activity of YAP/TEAD and Hippo pathway disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023130521_14112024_PF_FP_ABST
    Figure CN2023130521_14112024_PF_FP_ABST
Patent Text Reader

Abstract

A polycyclic compound having a structure as represented by formula I, a preparation method therefor, and a use thereof in the prevention and / or treatment of proliferative diseases, wherein the definitions of groups and substituents are as described in the description.
Need to check novelty before this filing date? Find Prior Art

Description

Polycyclic compounds and uses thereof Technical Field

[0001] The present invention relates to the field of medical technology, and specifically to polycyclic compounds for regulating the Hippo pathway, as well as preparation methods and uses thereof. The compounds are mainly used for the treatment or prevention of proliferative diseases (such as cancer), especially for regulating and treating related diseases caused by abnormal activity of YAP / TEAD. Background Art

[0002] The Hippo pathway is essentially composed of a core kinase cascade comprising the Ste-20 family of protein kinases MST1-2, the scaffolding protein Salvador, and the large tumor suppressor kinases LATS1-2, as well as the inhibitory transcriptional coactivators YAP (Yes1-associated protein) and TAZ (transcriptional coactivator with a PDZ-binding motif). YAP and TAZ are the primary effectors of the Hippo signaling pathway. Together with the nuclear TEAD (transcription enhancer-association domain), they act as transcription factors, increasing the expression of target genes such as CTGF (connective tissue growth factor) and CYR61. The Hippo pathway is an important regulator of cell growth, proliferation, and migration. TEAD transcription factors are at the core of the Hippo pathway and are crucial for regulating organ growth and wound repair. Dysregulation of TEAD and its regulatory cofactor, Yes-associated protein (YAP), has been implicated in numerous human cancers and hyperproliferative pathologies, and dysregulation of this pathway is frequently detected in human cancers. Like TEAD proteins, YAP and TAZ activation have been identified in many human tumors and are crucial for tumor initiation, progression, and metastasis. For example, YAP expression is elevated in patients with breast, ovarian, colon, liver, and pancreatic cancers and is associated with decreased survival. Consistent with this, activation or overexpression of YAP or TAZ enhances TEAD-dependent gene expression (e.g., CCN1, CTGF, ITGB2, and Birc5 / survivin) and promotes cell proliferation and migration in many cell types. Conversely, blocking the signaling that leads to the formation of the YAP / TAZ-TEAD complex or intervening to prevent the expression of many mitogenic TEAD target genes can significantly reduce cell proliferation and oncogenic transformation activity. In addition, the Hippo pathway also cross-talks with other signaling pathways such as Wnt, Notch, Hedgehog, and MAPK, thereby affecting multiple biological functions. Its dysfunction may be involved in many human diseases in addition to cancer. Therefore, the YAP-TEAD complex is a promising therapeutic target.

[0003] Summary of the Invention

[0004] The present invention aims to provide a compound represented by formula I, a preparation method thereof, and use thereof in preventing or treating proliferative diseases.

[0005] The first aspect of the present invention provides a compound represented by formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof,

[0006] in,

[0007] X1, X2, X3, and X4 are each independently selected from the group consisting of CR and N;

[0008] R is independently selected from the group consisting of H, halogen, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, aryl, heteroaryl;

[0009] A is selected from the following group:

[0010] B is selected from the following group:

[0011] L is selected from the group consisting of NR4, O, S, Se, sulfoxide, sulfone, CR2R3;

[0012] R1 is selected from the group consisting of H, CF3, CF2H, methyl, ethyl, isopropyl, cyclopropyl, trifluoromethoxy, SF5, tert-butyl;

[0013] R2 is independently selected from the following group: H, halogen, CN, NH2, hydroxyl, ester group, urea group, carbamate group, amide group, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, aryl, heteroaryl, among which NH2, ester, urea, carbamate, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 The hydrogen in the cycloalkoxy, aryl and heteroaryl groups can be arbitrarily substituted, and the substituents are halogen, CN, NH2, hydroxyl, ester, urea, carbamate, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, aryl, heteroaryl, or R2 and the structure to which it is connected form a 3-7 membered ring, or different R2s form a 3-7 membered ring;

[0014] R3, R4, and R5 are each independently selected from the group consisting of H, F, methyl, and CN;

[0015] m is independently selected from the following group: 0, 1, 2, 3, 4, 5, 6.

[0016] In another preferred embodiment, the "aryl" are each independently C 6-10 Aryl.

[0017] In another preferred embodiment, the “heteroaryl” is each independently a 5-10 membered heteroaryl group containing 1, 2, 3 or 4 heteroatoms selected from N, O or S.

[0018] In another preferred embodiment, X1 is N.

[0019] In another preferred embodiment, X2 is CH.

[0020] In another preferred embodiment, X3 is CH.

[0021] In another preferred embodiment, X4 is CH.

[0022] In another preferred embodiment, B is selected from the following group:

[0023] R2, R3, R4, and R5 are H;

[0024] m is 0.

[0025] In another preferred embodiment, m is selected from the following group: 0, 1, 2, 3.

[0026] In another preferred embodiment, the compound is as shown in Formula II, Formula III, or Formula IV:

[0027] wherein X2, A, B, L, and R1 are as defined above.

[0028] In another preferred embodiment,

[0029] A is selected from the following group:

[0030] B is selected from the following group:

[0031] R2, R3, R4, R5, and m are as defined above.

[0032] In another preferred embodiment, B is selected from the following group:

[0033] R2, R3, R4, R5, and m are as defined above.

[0034] The second aspect of the present invention provides a compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein the compound is selected from the group consisting of:

[0035] The third aspect of the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a safe and effective amount of one or more compounds described in the first aspect of the present invention or the second aspect of the present invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof.

[0036] The fourth aspect of the present invention provides a use of the pharmaceutical composition according to the third aspect of the present invention for preparing a medicament for preventing and / or treating a proliferative disease.

[0037] In another preferred embodiment, the proliferative disease is cancer.

[0038] In another preferred embodiment, the cancer is selected from the group consisting of brain glioma, prostate cancer, lung squamous cell carcinoma, breast cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, and squamous cell carcinoma.

[0039] The fifth aspect of the present invention provides a use of the pharmaceutical composition according to the third aspect of the present invention for preparing a drug, wherein the drug is used for a use selected from the group consisting of:

[0040] 1) Prevent and / or treat diseases caused by abnormal YAP / TEAD activity;

[0041] 2) Prevent and / or treat diseases caused by Hippo pathway dysregulation;

[0042] 3) Prevent and / or treat diseases related to YAP or TAZ or YAP / TAZ or TEAD or YAP / TEAD or YAP / TAZ / TEAD dysregulation.

[0043] In another preferred embodiment, the drug is used to prevent and / or treat diseases related to YAP / TEAD or YAP / TAZ / TEAD disorders.

[0044] In another preferred embodiment, the related disease caused by the abnormal activity of YAP / TEAD is cancer.

[0045] In another preferred embodiment, the disease related to the Hippo pathway disorder is cancer.

[0046] In another preferred embodiment, the related disease caused by YAP or TAZ or YAP / TAZ or TEAD or YAP / TEAD or YAP / TAZ / TEAD disorder is cancer.

[0047] In another preferred embodiment, the TEAD is selected from the following group: TEAD1, TEAD2, TEAD3, TEAD4, preferably TEAD1.

[0048] The sixth aspect of the present invention provides a compound according to the first aspect or the second aspect of the present invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof, in combination with a second drug for use in preventing and / or treating cancer;

[0049] The second drug is selected from the group consisting of ERK inhibitors, MEK inhibitors, KRAS inhibitors, BRAF inhibitors, EGFR inhibitors, Wnt inhibitors, and PD-1 inhibitors.

[0050] In another preferred embodiment, the ERK inhibitor is selected from the following group: AZD0364, Ulixertinib, or a combination thereof.

[0051] In another preferred embodiment, the MEK inhibitor is selected from the following group: cobimetinib, binimetinib, or a combination thereof.

[0052] In another preferred embodiment, the KRAS inhibitor is selected from the following group: Adagrasib (MRTX849), JNJ-74699157 (ARS-3248), JAB-3312, or a combination thereof.

[0053] In another preferred embodiment, the BRAF inhibitor is selected from the group consisting of sorafenib, regorafenib, or a combination thereof.

[0054] In another preferred embodiment, the EGFR inhibitor is selected from the group consisting of osimertinib, dacomitinib, gefitinib, or a combination thereof.

[0055] In another preferred embodiment, the Wnt inhibitor is selected from the following group: IWR-1, ETC-159, or a combination thereof.

[0056] In another preferred embodiment, the PD-1 inhibitor is selected from the group consisting of nivolumab, atezolizumab, pembrolizumab, or a combination thereof.

[0057] In another preferred embodiment, the cancer is selected from the group consisting of brain glioma, prostate cancer, lung squamous cell carcinoma, breast cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer, and squamous cell carcinoma.

[0058] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS

[0059] Figure 1. Thermal shifts of recombinant human TEAD1, TEAD2, TEAD3, and TEAD4 proteins alone or in the presence of T18. DETAILED DESCRIPTION

[0060] After long and in-depth research, the inventors prepared a novel compound of formula I through structural optimization, which has excellent proliferation inhibition activity and excellent YAP-TEAD inhibitory activity. On this basis, the inventors completed the present invention.

[0061] the term

[0062] In the present invention, unless otherwise specified, the terms used have the general meanings commonly known to those skilled in the art.

[0063] In the present invention, the term "halogen" refers to F, Cl, Br or I.

[0064] In the present invention, "C 1-6 The term "alkyl" refers to a straight or branched chain alkyl group containing 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, neopentyl, tert-pentyl, or the like.

[0065] In the present invention, the term "C 2-6 The term "alkenyl" refers to a straight or branched alkenyl group having 2 to 6 carbon atoms and containing one double bond, including but not limited to ethenyl, propenyl, butenyl, isobutenyl, pentenyl and hexenyl.

[0066] In the present invention, the term "C 2-6 The term "alkynyl" refers to a straight or branched chain alkynyl group having 2 to 6 carbon atoms and containing one triple bond, including but not limited to ethynyl, propynyl, butynyl, isobutynyl, pentynyl and hexynyl.

[0067] In the present invention, the term "C 3-6 "Cycloalkyl" includes groups selected from the group consisting of: C 3-6 Cycloalkyl, C 3-6 Cycloalkenyl, C 3-6 Cycloalkynyl.

[0068] In the present invention, the term "C 3-6 The term "cycloalkyl" refers to a cyclic alkyl group having 3 to 6 carbon atoms in the ring, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0069] In the present invention, the term "C 5-8 "Bridged cyclic group" refers to a cyclic alkyl group having a bridge and 5 to 8 carbon atoms, including but not limited to wait.

[0070] In the present invention, the term "C 1-6 "Alkoxy" refers to a straight or branched chain alkoxy group having 1 to 6 carbon atoms, including but not limited to methoxy, ethoxy, propoxy, isopropoxy and butoxy. Preferably, C 1-4 Alkoxy.

[0071] In the present invention, the term "heterocyclic group" refers to a 4-8 membered heterocyclic group containing 1, 2 or 3 heteroatoms selected from N, O and S, including (but not limited to) the following groups:

[0072] In the present invention, the term "aromatic ring" or "aryl group" has the same meaning, preferably "C 6-10 Aryl". The term "C 6-10 The term "aryl" refers to an aromatic ring group having 6 to 10 carbon atoms and containing no heteroatoms, such as phenyl and naphthyl.

[0073] In the present invention, the terms "aromatic heterocycle" or "heteroaryl" have the same meaning and refer to heteroaromatic groups containing one to multiple heteroatoms. For example, "C3-C10 heteroaryl" refers to an aromatic heterocycle containing 1 to 4 heteroatoms selected from oxygen, sulfur and nitrogen and 3 to 10 carbon atoms. Non-limiting examples include: furyl, thienyl, pyridyl, pyrazolyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is the heteroaryl ring. The heteroaryl group can be optionally substituted or unsubstituted.

[0074] In the present invention, the term "sulfoxide" refers to a

[0075] In the present invention, the term "sulfone" refers to a

[0076] In the present invention, the term "ester group" refers to the structure

[0077] In the present invention, the term "urea group" refers to a structure

[0078] In the present invention, the term "carbamate group" refers to a

[0079] In the present invention, the term "amide group" refers to a structure

[0080] In the present invention, the term "halo" means substituted with halogen.

[0081] In the present invention, the term "deuterated" means substituted with deuterium.

[0082] In the present invention, the term "substituted" refers to the replacement of one or more hydrogen atoms on a specific group with a specific substituent. The specific substituent is the substituent described above or the substituent appearing in the examples. Unless otherwise specified, a substituted group may have a substituent selected from the specific group at any substitutable position of the group, and the substituent may be the same or different at each position. It will be understood by those skilled in the art that the combinations of substituents contemplated by the present invention are those that are stable or chemically feasible. The substituents include, but are not limited to, halogen, hydroxyl, carboxyl (-COOH), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, 3- to 12-membered heterocyclyl, aryl, heteroaryl, C1-C8 aldehyde, C2-C10 acyl, C2-C10 ester, amino, C1-C6 alkoxy, C1-C10 sulfonyl, and the like.

[0083] In the present invention, the term 1-6 refers to 1, 2, 3, 4, 5 or 6. Other similar terms independently have similar meanings. The term "plurality" refers to 2-6, such as 2, 3, 4, 5 or 6.

[0084] It should be understood that when a group is present at multiple different positions in a compound, its definition at each position is independent of each other and may be the same or different. That is, the term "selected from the group:" has the same meaning as the term "each independently selected from the group:".

[0085] Compounds and preparation methods

[0086] The present invention provides a compound represented by formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof,

[0087] wherein each group is as defined above.

[0088] In another preferred embodiment, in the compound, any one of R1, X1, X2, X3, X4, L, A, and B is independently a corresponding group in the specific compound.

[0089] In another preferred embodiment, the compound is the specific compound shown in the present invention.

[0090] As used herein, the term "pharmaceutically acceptable salt" refers to a salt of a compound of the present invention formed with an acid or base that is suitable for pharmaceutical use. Pharmaceutically acceptable salts include inorganic salts and organic salts. A preferred class of salts are salts formed with a compound of the present invention and an acid. Suitable acids for forming salts include, but are not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid, and naphthalenesulfonic acid; and amino acids such as proline, phenylalanine, aspartic acid, and glutamic acid.

[0091] Another preferred salt is a salt of the compound of the present invention formed with a base, such as an alkali metal salt (e.g., sodium salt or potassium salt), an alkaline earth metal salt (e.g., magnesium salt or calcium salt), an ammonium salt (e.g., lower alkanolammonium salt and other pharmaceutically acceptable amine salts), for example, methylamine salt, ethylamine salt, propylamine salt, dimethylamine salt, trimethylamine salt, diethylamine salt, triethylamine salt, tert-butylamine salt, ethylenediamine salt, hydroxyethylamine salt, dihydroxyethylamine salt, trihydroxyethylamine salt, and amine salts formed from morpholine, piperazine, and lysine, respectively.

[0092] The term "solvate" refers to a complex in which the compound of the present invention is coordinated with solvent molecules to form a specific ratio.

[0093] In addition, the compounds of the present invention also include prodrugs of the compounds represented by Formula I. The term "prodrug" includes compounds that may be biologically active or inactive, and that, when administered using appropriate methods, undergo metabolism or chemical reactions in the human body to transform into a compound of Formula I, or a salt or solution of a compound of Formula I. Such prodrugs include (but are not limited to) carboxylate esters, carbonate esters, phosphate esters, nitrate esters, sulfate esters, sulfone esters, sulfoxide esters, amino compounds, carbamates, azo compounds, phosphoramides, glucosides, ethers, acetals, and the like of the compounds.

[0094] It should be understood that the compounds of the present invention can also be conveniently prepared by optionally combining various synthetic methods described in this specification or known in the art. Such combinations can be easily performed by those skilled in the art to which the present invention belongs.

[0095] Typically, the raw materials and reagents used in the process for preparing the compounds of the present invention can be purchased through commercial channels unless otherwise specified.

[0096] Pharmaceutical compositions and methods of administration

[0097] The present invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more safe and effective amounts of the compound or a pharmaceutically acceptable salt, solvate or prodrug thereof.

[0098] Since the compounds of the present invention have excellent anti-tumor activity, the compounds of the present invention and their various crystal forms, pharmaceutically acceptable inorganic or organic salts, hydrates or solvates, and pharmaceutical compositions containing the compounds of the present invention as the main active ingredient can be used to treat, prevent and alleviate tumor-related diseases.

[0099] The pharmaceutical composition of the present invention comprises a safe and effective amount of a compound of the present invention or a pharmacologically acceptable salt thereof, and a pharmacologically acceptable excipient or carrier. "Safe and effective amount" means an amount of the compound sufficient to significantly improve the condition without causing serious side effects. Typically, the pharmaceutical composition contains 1-2000 mg of the compound of the present invention per dose, more preferably 10-1000 mg of the compound of the present invention per dose. Preferably, "one dose" is one capsule or tablet.

[0100] "Pharmaceutically acceptable carriers" refer to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as Tween ), wetting agents (such as sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0101] The pharmaceutical composition is in the form of injection, capsule, tablet, pill, powder or granule.

[0102] There is no particular limitation on the administration of the compound or pharmaceutical composition of the present invention. Representative administration routes include (but are not limited to): oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.

[0103] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

[0104] Solid dosage forms such as tablets, dragees, capsules, pills, and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifying agents, and the release of the active compound or compounds in such compositions can be delayed in a certain portion of the digestive tract. Examples of useful encapsulating components are polymeric substances and waxes. If desired, the active compound can also be microencapsulated with one or more of the above-mentioned excipients.

[0105] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, or mixtures thereof.

[0106] Besides such inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[0107] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances.

[0108] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.

[0109] Dosage forms for topical administration of the compounds of this invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.

[0110] The compounds of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds (such as anti-tumor drugs).

[0111] The treatment method of the present invention can be used alone or in combination with other treatment methods or therapeutic drugs.

[0112] When using a pharmaceutical composition, a safe and effective amount of the compound of the present invention is administered to a mammal (e.g., a human) in need of treatment, wherein the dosage is a pharmaceutically effective dosage. For a 60 kg human, the daily dosage is generally 1 to 2000 mg, preferably 50 to 1000 mg. Of course, the specific dosage will also take into account factors such as the route of administration and the patient's health condition, all of which are within the skill of a skilled physician.

[0113] Compared with the prior art, the present invention has the following main advantages:

[0114] (1) The compound has excellent proliferation inhibitory activity;

[0115] (2) The compound has excellent YAP-TEAD inhibitory activity;

[0116] (3) The compound has excellent pharmacokinetic properties;

[0117] (4) The compound has excellent blood-brain barrier (BBB) ​​permeability.

[0118] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, were generally performed under conventional conditions such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are calculated by weight.

[0119] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those familiar to those skilled in the art. Furthermore, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred embodiments and materials described herein are for illustrative purposes only.

[0120] Example 1

[0121] Compounds synthesized by the present invention:

[0122] The synthetic route is as follows:

[0123] The experimental process is as follows:

[0124] (1) Synthesis of T2-2

[0125] T2-1 (3.6 g, 12.54 mmol, 1.0 eq), p-trifluoroaniline (2.02 g, 12.54 mmol, 1 eq), CS2CO3 (8.17 g, 25.08 mmol, 2 eq), Xanthpos (727.7 mg, 1.25 mmol, 10% eq), Pd(OAc)2 (140.77 mg, 0.627 mmol, 5% eqiv), and 50 ml of ultra-dry 1,4-dioxane were added sequentially into a microwave tube, and the reaction was carried out at 150°C under microwave for 45 minutes.

[0126] After the reaction was completed, the mixture was cooled to room temperature, 40 mL of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography using PE 100%, PE:EA=500:1 to obtain 1.3 g of T2-2.

[0127] (2) Synthesis of T2-3

[0128] To a 100 mL single-necked flask were added T2-2 (1.3 g, 3.55 mmol, 1.0 eq), pinacol borate (1.32 g, 4.26 mmol, 1.2 eqiv), potassium carbonate (981.2 mg, 7.1 mmol, 2.0 eqiv) water / 1,4-dioxane (1 / 10) (1.5 mL / 15 mL), and Pd(dppf)Cl2 (129.75 mg, 0.178 mmol, 5% eq). The atmosphere was purged with nitrogen three times and placed in an oil bath, heated to 105°C for 16 h. After the reaction was completed and cooled to room temperature, the mixture was diluted with EA, filtered through celite, and 10 mL of water was added. The mixture was extracted with ethyl acetate (20 ml*3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was dried by suction and passed through a column to obtain 1.4 g of T2-3 (pale yellow solid).

[0129] (3) Synthesis of T2-4

[0130] T2-3 (1.4 g) was dissolved in ethanol (15 mL), and triphenylphosphine rhodium chloride (210 mg, 20%) was added. The mixture was reacted under high-pressure hydrogen for 24 h. If the raw material was not completely reacted, T2-4 (1.4 g) was obtained by column chromatography (white solid).

[0131] (4) Synthesis of T2-5

[0132] T2-4 (1.5 g, 3.29 mmol, 1.0 eq), T2-4a (1.72 g, 8.23 ​​mmol, 2.5 eq), NaHCO3 (1.24 g, 14.81 mmol, 4.5 eq), Pd(OAC)2 (73.7 mg, 0.33 mmol, 0.1 eq) and PCy3 (184.53 mg, 0.66 mmol, 0.2 eq) were added to the reaction flask, and the solvent was 1,4-dioxane / EtOH / water (7:2:1) (11.9 ml / 3.4 ml / 1.7 ml). After nitrogen replacement three times, the mixture was placed in an oil bath and heated to 105 degrees for 12 hours. After the reaction was completed and the temperature was lowered to room temperature, 20 mL of water was added, and the mixture was extracted with ethyl acetate (25 mL * 3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was filtered and dried by column to obtain 1.53 g of product T2-5.

[0133] (5) Synthesis of Compound T2-6

[0134] Compound T2-5 (1.53 g) was added to DCM (10 ml), followed by the addition of HCl / dioxane (25 mL, 4 M), and the mixture was reacted at room temperature overnight to obtain 1.6 g of white solid T2-6 after direct spin drying.

[0135] (6) Synthesis of Compound T2

[0136] Compound T2-6 (1.6 mg, 4 mmol, 1.0 eq), triethylamine (1.2 g, 12 mmol, 3.0 eq), and DCM (12 ml) were added to a reaction flask. A solution of acryloyl chloride (397.3 mg, 4.4 mmol, 1.1 eq) in DCM (6 ml) was then added dropwise at zero temperature and stirred overnight at room temperature. The solution was washed with 0.1 N HCl and extracted with EA. The product was then purified by column chromatography using petroleum ether and EA to yield 452 mg of T2 as a white solid.

[0137] 1H NMR(400MHz,Chloroform-d)δ8.32(d,J=2.2Hz,1H),7.72(s,1H),7.62-7.48(m,6H),6.63(dd,J=16.8,10.6Hz,1H),6.46-6.26(m,2H),5.74(dd,J=1 0.5,1.9Hz,1H),4.92(d,J=13.4Hz,1H),4.24-4.16(m,1H),3.96(s,3H),3 .24(t,J=12.8Hz,1H),2.95-2.73(m,2H),2.07-1.98(m,2H),1.73(s,2H).

[0138] Referring to the synthesis method of compound T2, the following compound was synthesized:

[0139] Example 2

[0140] Compound T18 synthesized by the present invention:

[0141] The synthetic route is as follows:

[0142] The experimental process is as follows:

[0143] (1) Synthesis of T18-2

[0144] T18-1 (3.6 g, 12.54 mmol, 1.0 eq), p-trifluoroaniline (2.02 g, 12.54 mmol, 1 eq), CS2CO3 (8.17 g, 25.08 mmol, 2 eq), Xanthpos (727.7 mg, 1.25 mmol, 10% eq), Pd(OAc)2 (140.77 mg, 0.627 mmol, 5% eq), and 50 ml of ultra-dry 1,4-dioxane were added sequentially to a microwave tube, and the reaction was carried out at 150°C under microwave for 45 minutes.

[0145] After the reaction was completed, the mixture was cooled to room temperature, 40 mL of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography using a mobile phase (PE 100%, PE:EA = 500:1) to obtain 1.3 g of T18-2.

[0146] (2) Synthesis of T18-3

[0147] To a 100 mL single-necked flask were added T18-2 (1.0 g, 3.17 mmol, 1.0 eq), S1 (1.0 g, 3.80 mmol, 1.2 eq), potassium carbonate (780 mg, 6.34 mmol, 2.0 eq) in water / 1,4-dioxane (1 / 10) (1 mL / 10 mL), and Pd(dppf)Cl2 (200 mg, 0.317 mmol, 10% eq). The atmosphere was purged with nitrogen three times and placed in an oil bath, heated to 105°C for 16 h. After the reaction was completed and cooled to room temperature, the mixture was diluted with EA, filtered through celite, and 10 mL of water was added. The mixture was extracted with ethyl acetate (20 ml*3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was dried by suction and passed through a column to obtain 900 mg of T18-3 (pale yellow liquid).

[0148] (3) Synthesis of T18-4

[0149] T18-3 (900 mg) was dissolved in ethanol (10 mL), and triphenylphosphine rhodium chloride (210 mg, 20%) was added. The mixture was reacted at 60°C under high-pressure hydrogen for 16 h. After the reaction, triphenylphosphine rhodium chloride was removed by filtration through a celite pad and passed through a column to obtain 820 mg of T18-4 (red solid).

[0150] (4) Synthesis of T18-5

[0151] T18-4 (800 mg, 1.855 mmol, 1.0 eq), S2 (967 mg, 4.63 mmol, 2.5 eq), NaHCO3 (710 mg, 8.34 mmol, 4.5 eq), Pd(OAC)2 (41 mg, 0.1855 mmol, 0.1 eq) and PCy3 (103.6 mg, 0.371 mmol, 0.2 eq) were added to the reaction flask, and the solvent was added with 1,4-dioxane / EtOH / water (7:2:1) (11.9 ml / 3.4 ml / 1.7 ml). After nitrogen was replaced three times, the mixture was placed in an oil bath and heated to 105 degrees for 12 hours. After the reaction was completed and cooled to room temperature, 20 mL of water was added and extracted with ethyl acetate (25 ml * 3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was dried by spin drying and passed through a column to obtain 500 mg of product T18-5.

[0152] (5) Synthesis of Compound T18-6

[0153] Compound T18-5 (500 mg) was added to DCM (10 ml), followed by the addition of HCl / dioxane (10 mL, 4 M), and the mixture was reacted at room temperature overnight to obtain 570 mg of a white solid after direct spin drying.

[0154] (6) Synthesis of Compound T18

[0155] Compound T18-6 (570 mg, 1.47 mmol, 1.0 eq), triethylamine (445 mg, 4.4 mmol, 3.0 eq), and DCM (5 ml) were added to a reaction flask. A solution of acryloyl chloride (145 mg, 1.61 mmol, 1.1 eq) in DCM (2 ml) was then added dropwise at zero temperature and stirred overnight at room temperature. The solution was washed with 0.1 N HCl and extracted with EA. The product was then purified by column chromatography using petroleum ether and EA to afford 130 mg of T18 (white solid). The resulting solid was subjected to chiral separation to afford 15 mg of T19 and 15 mg of T20.

[0156] Referring to the synthesis method of compound T18, the following compounds were synthesized:

[0157] Example 3

[0158] Compound T22 synthesized by the present invention:

[0159] The synthetic route is as follows:

[0160] The experimental process is as follows:

[0161] (1) Synthesis of T22-2

[0162] T22-1 (3.6 g, 12.54 mmol, 1.0 eq), p-trifluoroaniline (2.02 g, 12.54 mmol, 1 eq), CS2CO3 (8.17 g, 25.08 mmol, 2 eq), Xanthpos (727.7 mg, 1.25 mmol, 10% eq), Pd(OAc)2 (140.77 mg, 0.627 mmol, 5% eq), and 50 ml of ultra-dry 1,4-dioxane were added to a microwave tube and reacted at 150°C for 45 minutes. After the reaction was completed, the mixture was cooled to room temperature, 40 mL of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain the crude product, which was then purified by column chromatography using 100% PE (PE:EA = 500:1) to obtain 1.3 g of T22-2.

[0163] (2) Synthesis of T22-3

[0164] To a 100 mL single-necked flask were added T22-2 (1.0 g, 3.17 mmol, 1.0 eq), T22-2b (1.0 g, 3.80 mmol, 1.2 eq), potassium carbonate (780 mg, 6.34 mmol, 2.0 eq) in water / 1,4-dioxane (1 / 10) (1 mL / 10 mL), and Pd(dppf)Cl2 (200 mg, 0.317 mmol, 10% eq). The atmosphere was purged with nitrogen three times and placed in an oil bath, heated to 105°C for 16 h. After the reaction was completed and cooled to room temperature, the mixture was diluted with EA, filtered through celite, and 10 mL of water was added. The mixture was extracted with ethyl acetate (20 ml*3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was filtered and passed through a column to obtain 900 mg of T22-3 (pale yellow liquid).

[0165] (3) Synthesis of T22-4

[0166] T22-3 (900 mg) was dissolved in ethanol (10 mL), and triphenylphosphine rhodium chloride (210 mg, 20%) was added. The mixture was reacted at 60°C under high-pressure hydrogen for 16 h. After the reaction, triphenylphosphine rhodium chloride was removed by filtration through a celite pad. Column chromatography gave T22-4 (1.0 g) (red solid).

[0167] (4) Synthesis of T22-5

[0168] T22-4 (1.0 g, 2.19 mmol, 1.0 eq), T22-4b (370 mg, 4.38 mmol, 2.0 eq), K3PO4 (140 mg, 6.59 mmol, 3.0 eq), Pd(OAC)2 (50 mg, 0.219 mmol, 0.1 eq) and PCy3 (123 mg, 0.438 mmol, 0.2 eq) were added to a reaction flask. The solvent was added with toluene / water (10:1) (10 ml / 1 ml). After nitrogen was replaced three times, the mixture was placed in an oil bath and heated to 100 degrees for 16 hours. After the reaction was completed, the mixture was cooled to room temperature and filtered. The filtrate was spin-dried and column chromatography was performed to obtain 1.0 g of product T22-5.

[0169] (5) Synthesis of Compound T22-6

[0170] Compound T22-5 (1.0 g) was added to DCM (10 ml), followed by HCl / dioxane (10 mL, 4 M), and then reacted at room temperature overnight to obtain 1.0 g of a white solid with a content of 78% after direct spin drying.

[0171] (6) Synthesis of Compound T22

[0172] Compound T22-6 (1.0 g, 2.7 mmol, 1.0 eq), triethylamine (840 mg, 8.1 mmol, 3.0 eq), and DCM (10 ml) were added to a reaction flask and stirred on ice for 10 min. Acryloyl chloride (274 mg, 2.97 mmol, 1.1 eq) in DCM (5 ml) was then added dropwise at zero temperature and stirred overnight at room temperature. The solution was washed with 0.1 N HCl and extracted with EA. The product was then purified by column chromatography using petroleum ether and EA to yield 200 mg of T22 as a white solid.

[0173] 1 H NMR(400MHz,Chloroform-d)δ8.00(d,J=2.3Hz,1H),7.52(d,J=8.7Hz,2H),7.38(d,J=8.7Hz,2H),7.15(d,J= 2.4Hz,1H),6.62(dd,J=16.8,10.6Hz,1H),6.33(dd,J=16.8,1.9Hz,1H),6.23(s,1H),5.73(dd,J=10.5,1.9H z,1H),4.89(d,J=13.4Hz,1H),4.17(d,J=13.7Hz,1H),3.21(t,J=12.9Hz,1H),2.88-2.66(m,2H),1.95(d,J= 13.4Hz,2H),1.85(tt,J=8.5,5.1Hz,1H),1.02-0.93(m,2H),0.92-0.77(m,2H),0.66(dt,J=6.7,4.7Hz,2H).

[0174] Referring to the synthesis method of compound T22, the following compounds were synthesized:

[0175] Example 4

[0176] Compound T24 synthesized by the present invention:

[0177] The synthetic route is as follows:

[0178] The experimental process is as follows:

[0179] (1) Synthesis of T24-2

[0180] T24-1 (3.6 g, 12.54 mmol, 1.0 eq), p-trifluoroaniline (2.02 g, 12.54 mmol, 1 eq), CS2CO3 (8.17 g, 25.08 mmol, 2 eq), Xanthpos (727.7 mg, 1.25 mmol, 10% eq), Pd(OAc)2 (140.77 mg, 0.627 mmol, 5% eq), and 50 ml of ultra-dry 1,4-dioxane were added sequentially to a microwave tube, and the reaction was carried out at 150°C under microwave conditions for 45 minutes.

[0181] After the reaction was completed, the mixture was cooled to room temperature, 40 mL of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography using PE 100%, PE:EA=500:1 to obtain 1.3 g of T24-2.

[0182] (2) Synthesis of T24-3

[0183] To a 100 mL single-necked flask were added T24-2 (1.0 g, 3.17 mmol, 1.0 eq), S1 (1.0 g, 3.80 mmol, 1.2 eq), potassium carbonate (780 mg, 6.34 mmol, 2.0 eq) in water / 1,4-dioxane (1 / 10) (1 mL / 10 mL), and Pd(dppf)Cl2 (200 mg, 0.317 mmol, 10% eq). The atmosphere was purged with nitrogen three times and placed in an oil bath, heated to 105°C for 16 h. After the reaction was completed and cooled to room temperature, the mixture was diluted with EA, filtered through celite, and 10 mL of water was added. The mixture was extracted with ethyl acetate (20 ml*3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was dried by suction and passed through a column to obtain 900 mg of T24-3 (pale yellow liquid).

[0184] (3) Synthesis of T24-4

[0185] T24-3 (900 mg) was dissolved in ethanol (10 mL), and triphenylphosphine rhodium chloride (210 mg, 20%) was added. The mixture was reacted at 60°C under high-pressure hydrogen for 16 h. After the reaction, triphenylphosphine rhodium chloride was removed by filtration through a celite pad. Column chromatography gave T24-4 1.0 g (red solid).

[0186] (4) Synthesis of T24-5

[0187] T24-4 (900 mg, 1.98 mmol, 1.0 eq), T24-4a (338 mg, 3.01 mmol, 1.5 eq), K2CO3 (818 mg, 5.94 mmol, 3.0 eq), Pd2(dba)3 (180 mg, 0.198 mmol, 0.1 eq) and PCy3 (123 mg, 0.438 mmol, 0.2 eq) were added to a reaction flask, and the solvent was added with toluene / water (10:1) (18 ml / 1.8 ml). After nitrogen was replaced three times, the mixture was placed in an oil bath and heated to 100 degrees for 16 hours. After the reaction was completed, the mixture was cooled to room temperature and filtered, the filtrate was spin-dried, and column chromatography was performed to obtain 1.0 g of product T24-5.

[0188] (5) Synthesis of T24-6

[0189] T24-5 (1.0 g) was added to MeOH (10 ml), followed by the addition of Pd(OH)2 (100 mg, 10%), and the mixture was allowed to react overnight at room temperature. After the reaction, the palladium catalyst was removed by filtration, and 500 mg of T24-6 was obtained by column chromatography.

[0190] (6) Synthesis of T24-7

[0191] T24-6 (500 mg) was added to DCM (5 ml), and HCl / dioxane (5 ml, 4 M) was added. The mixture was stirred at room temperature for 3 h. After the reaction was completed, the mixture was directly spin-dried to obtain 400 mg of product T24-7.

[0192] (7) Synthesis of Compound T24

[0193] Compound 24-7 (400 mg, 1.02 mmol, 1.0 eq), triethylamine (310 mg, 3.07 mmol, 3.0 eq), and DCM (4 ml) were added to a reaction flask and stirred on ice for 10 min. Acryloyl chloride (101 mg, 1.12 mmol, 1.1 eq) in DCM (2 ml) was then added dropwise at zero temperature, and the reaction was stirred at room temperature for 3 h. After the reaction, the solution was washed with 0.1 N HCl and extracted with EA. The product was then purified by column chromatography using petroleum ether and EA to yield 150 mg of T24 as a white solid.

[0194] 1H NMR(400MHz,Chloroform-d)δ8.07(d,J=2.3Hz,1H),7.53(d,J=8.4Hz,2H),7.41(d,J=8.4Hz,2H),7.34(d,J=2.3Hz,1H),6.63(dd,J=16.8, 10.5Hz,1H),6.38-6.29(m,2H),5.73(dd,J=10.5,1.9Hz,1H),4.89(d,J=13.2Hz,1H),4.17(d,J=13.9Hz,1H),3.21(t,J=13.1Hz,1H),3.01- 2.78(m,3H),2.06(t,J=9.2Hz,2H),1.97(d,J=13.8Hz,2H),1.82(td,J=9.0,8.5,5.0Hz,2H),1.77-1.66(m,4H),1.58-1.51(m,2H).

[0195] Referring to the synthesis method of compound T24, the following compounds were synthesized:

[0196] Example 5

[0197] Compound T14 synthesized by the present invention:

[0198] The synthetic route is as follows:

[0199] The experimental process is as follows:

[0200] (1) Synthesis of T14-2

[0201] T24-4 (500 mg, 1.09 mmol, 1.0 eq), T14-1 (298 mg, 2.19 mmol, 2.0 eq), K3PO4 (700 mg, 3.29 mmol, 3.0 eq), Pd(OAC)2 (25 mg, 0.109 mmol, 0.1 eq) and PCy3 (60 mg, 0.219 mmol, 0.2 eq) were added to a reaction flask, and the solvent was added with toluene / water (10:1) (10 ml / 1 ml). After nitrogen was replaced three times, the mixture was placed in an oil bath and heated to 100 degrees for 16 hours. After the reaction was completed, the mixture was cooled to room temperature and filtered, the filtrate was spin-dried, and column chromatography was performed to obtain 400 mg of the product T14-2.

[0202] (2) Synthesis of T14-3

[0203] Compound T14-2 (400 mg) was added to DCM (5 ml), followed by the addition of HCl / dioxane (5 mL, 4 M), and then reacted at room temperature overnight to obtain 500 mg of T14-3 as a white solid after direct spin drying.

[0204] (3) Synthesis of compound T14

[0205] Compound T14-3 (500 mg, 1.2 mmol, 1.0 eq), triethylamine (360 mg, 3.6 mmol, 3.0 eq), and DCM (5 ml) were added to a reaction flask and stirred on ice for 10 min. Acryloyl chloride (120 mg, 1.32 mmol, 1.1 eq) in DCM (2 ml) was then added dropwise at zero temperature and stirred overnight at room temperature. The solution was washed with 0.1 N HCl and extracted with EA. The product was then purified by column chromatography using petroleum ether and EA to yield 100 mg of T14 as a white solid.

[0206] 1 H NMR(400MHz,Chloroform-d)δ8.41(d,J=2.3Hz,1H),7.64(d,J=2.4Hz,1H),7.56(d,J=1.7Hz,4H), 7.46-7.40(m,2H),7.28(s,1H),7.26(s,1H),6.63(dd,J=16.8,10.6Hz,1H),6.41(s,1H),6.33(dd, J=16.8,1.9Hz,1H),5.74(dd,J=10.6,1.9Hz,1H),4.93(d,J=13.4Hz,1H),4.21(d,J=13.7Hz,1H), 3.26(t,J=13.2Hz,1H),2.98-2.69(m,2H),2.41(s,3H),2.04(d,J=13.1Hz,2H),1.86-1.67(m,2H).

[0207] Referring to the synthesis method of compound T14, the following compounds were synthesized:

[0208] Example 6

[0209] Compound T16 synthesized by the present invention:

[0210] The synthetic route is as follows:

[0211] The experimental process is as follows:

[0212] (1) Synthesis of T16-1

[0213] Compound T24-4 (600 mg, 1.0 eq), 3-pyridineboronic acid (179 mg, 1.1 eq), K3PO4 (844 mg, 3.0 eq), Pd2(dba)3 (121 mg, 0.10 eq), and PCy3 (89 mg, 0.24 eq) were dissolved in 1,4-dioxane (6 mL) and H2O (0.6 mL). The atmosphere was replaced with N2, and the mixture was heated to 100°C and stirred overnight. TLC indicated that the reaction was complete. The mixture was filtered from celite, dried, and purified by column chromatography to afford T16-1 (412 mg).

[0214] (2) Synthesis of T16-2

[0215] T16-1 (412 mg) was dissolved in dichloromethane (4 mL) and 1,4-dioxane hydrochloride (8 ml), the atmosphere was replaced with N2, and the reaction was carried out at room temperature for about 3 h. TLC showed that the reaction of the raw material was complete. The solvent was dried to obtain the crude product T16-2 (412 mg).

[0216] (3) Synthesis of T16

[0217] Crude T16-2 (412 mg, 1.0 eq) was dissolved in dichloromethane (2 mL). TEA (378.4 mg, 3.0 eq) was added in an ice bath. A mixture of acryloyl chloride (123.6 mg, 1.1 eq) and dichloromethane (2 mL) was slowly added dropwise under N2 protection. The mixture was then allowed to react at room temperature for approximately 4 h. LCMS indicated that the reaction was complete. The sample was then spin-dried and purified by column chromatography to yield T16 (212 mg).

[0218] 1 H NMR (400MHz, Chloroform-d) δ8.80 (s, 1H), 8.64-8.58 (m, 1H), 8.41 (d, J = 2.3Hz, 1H), 7.84 (dt, J = 7. 9,1.9Hz,1H),7.66-7.55(m,5H),7.40(dd,J=7.9,4.8Hz,1H),6.64(dd,J=16.8,10.5Hz,1H),6.52(s ,1H),6.33(dd,J=16.9,1.9Hz,1H),5.74(dd,J=10.5,1.9Hz,1H),4.94(d,J=13.4Hz,1H),4.23(d,J =13.8Hz,1H),3.28(t,J=12.9Hz,1H),2.94-2.76(m,2H),2.07(d,J=13.4Hz,2H),1.35-1.25(m,2H).

[0219] Referring to the synthesis method of compound T16, the following compounds were synthesized:

[0220] Example 7

[0221] Compound T26 synthesized by the present invention:

[0222] The synthetic route is as follows:

[0223] The experimental process is as follows:

[0224] (1) Synthesis of T26-2

[0225] T26-1 (2 g, 7.41 mmol, 1.0 eq), p-trifluorophenol (1.44 g, 8.89 mmol, 1.2 eq), CS2CO3 (4.8 g, 14.81 mmol, 2 eq), TMEDA (86 mg, 0.74 mmol, 10% eq), CuI (140 mg, 0.74 mmol, 10% eqiv), and 20 ml of DMSO were added to a microwave tube in sequence, and the mixture was heated under reflux at 110°C for 20 h.

[0226] After the reaction was completed, the mixture was cooled to room temperature, 40 mL of water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The crude product was purified by column chromatography to obtain 1.9 g of T26-2.

[0227] (2) Synthesis of T26-3

[0228] To a 100 mL single-necked flask were added T26-2 (1.97 g, 5.64 mmol, 1.0 eq), pinacol borate (2.09 g, 6.77 mmol, 1.2 eqiv), potassium carbonate (1.56 g, 11.28 mmol, 2.0 eqiv) in water / 1,4-dioxane (1 / 10) (1.9 mL / 19 mL), and Pd(dppf)Cl2 (206.4 mg, 0.282 mmol, 5% eq). The atmosphere was purged with nitrogen three times and placed in an oil bath, heated to 105°C for 16 h. After the reaction was completed and cooled to room temperature, the mixture was diluted with EA, filtered through celite, and 10 mL of water was added. The mixture was extracted with ethyl acetate (20 mL*3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was dried by suction and passed through a column to obtain 2.1 g of T26-3 (pale yellow solid).

[0229] (3) Synthesis of T26-4

[0230] T26-3 (2.1 g) was dissolved in ethanol (30 mL), and triphenylphosphine rhodium chloride (450 mg, 20%) was added. The mixture was reacted under high-pressure hydrogen for 24 h. If the raw material was not completely reacted, 1.9 g of T26-4 (white solid) was obtained after column chromatography.

[0231] (4) Synthesis of T26-5

[0232] T26-4 (1.1 g, 2.41 mmol, 1.0 eq), S2 (1.25 g, 6.03 mmol, 2.5 eq), NaHCO3 (911 mg, 10.85 mmol, 4.5 eq), Pd(OAC)2 (54 mg, 0.24 mmol, 0.1 eq) and PCy3 (135.2 mg, 0.48 mmol, 0.2 eq) were added to a reaction flask. The solvent was added with 1,4-dioxane / EtOH / water (7:2:1) (7 ml / 2 ml / 1 ml). After nitrogen was replaced three times, the mixture was placed in an oil bath and heated to 105 degrees for 12 hours. After the reaction was completed and cooled to room temperature, 20 mL of water was added and extracted with ethyl acetate (25 ml * 3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was dried by spin drying and passed through a column to obtain 1.1 g of product T26-5.

[0233] (5) Synthesis of compound T26-6

[0234] Compound 5 (1.1 g) was added to DCM (10 ml), followed by the addition of HCl / dioxane (20 mL, 4 M), and the mixture was reacted at room temperature overnight to obtain 900 mg of a white solid 6 after direct spin drying.

[0235] (6) Synthesis of Compound T26

[0236] Compound T26-6 (820 mg, 2.03 mmol, 1.0 eq), triethylamine (615.1 mg, 6.09 mmol, 3.0 eq), and DCM (8 ml) were added to a reaction flask. A solution of acryloyl chloride (202.11 mg, 2.33 mmol, 1.1 eq) in DCM (6 ml) was then added dropwise at zero temperature and stirred overnight at room temperature. The solution was washed with 0.1 N HCl and extracted with EA. The product was then purified by column chromatography using petroleum ether and EA to yield 170 mg of T26 as a white solid.

[0237] 1H NMR(400MHz,Chloroform-d)δ8.38(s,1H),8.05(s,1H),7.67(d,J=8.2Hz,2H),7.40(s, 1H),7.21(s,2H),6.63(dd,J=16.9,10.8Hz,1H),6.49(s,1H),6.31(d,J=16.8Hz,1H),5 .71(d,J=10.6Hz,1H),4.88(d,J=13.1Hz,1H),4.16(d,J=13.8Hz,1H),3.96(s,3H),3.2 4(d,J=12.7Hz,2H),2.77(t,J=13.0Hz,1H),2.05(d,J=13.1Hz,2H),1.90-1.78(m,2H).

[0238] Referring to the synthesis method of compound T26, the following compounds were synthesized:

[0239] Example 8

[0240] Compound T28 synthesized by the present invention:

[0241] The synthetic route is as follows:

[0242] The experimental process is as follows:

[0243] (1) Synthesis of T28-2

[0244] 1,2-Dibromoethane (78.5 mg, 0.418 mmol, 0.1 eq) was added to a THF solution of zinc powder (410.7 mg, 6.27 mmol, 1.5 eq), heated to reflux for 1 h, cooled to room temperature, trimethylsilyl chloride (45.4 mg, 0.418 mmol, 0.1 eq) was added dropwise, stirred for 1 h, and then a THF solution of trifluoromethylbenzyl bromide (1 g, 4.18 mmol, 1 eq) was added dropwise. The reaction was carried out at 60°C for 1 h. After cooling to room temperature, T28-1 (1.36 g, 5.02 mmol, 1.2 eq) and Pd(phh3)4 (97 mg, 0.084 mmol, 0.02 eq) were added, heated to reflux for 1 h, and finally stirred at room temperature for 18 h. After the reaction, the mixture was filtered through celite and quenched with EA and aqueous sodium carbonate solution. The solid precipitated and the filtrate was filtered and extracted with water and EA, washed once with saturated NaCl, dried over anhydrous sodium sulfate, concentrated, mixed and passed through a column to obtain 600 mg of T28-2.

[0245] 1H NMR (400MHz, Chloroform-d) δ8.47(d,J=2.2Hz,1H),7.88(d,J=2.2Hz,1H),7.54(d,J=8.0Hz,2H),7.40(d,J=7.9Hz,2H),4.36(s,2H).

[0246] (2) Synthesis of T28-3

[0247] T28-2 (2 g, 5.731 mmol, 1.0 eq), pinacol borate (2.12 g, 6.88 mmol, 1.2 eqiv), potassium carbonate (1.58 mg, 11.46 mmol, 2.0 eqiv) in water / 1,4-dioxane (1 / 10) (2 mL / 20 mL), and Pd(dppf)Cl2 (209.8 mg, 0.287 mmol, 5% eq) were added sequentially to a 100 mL single-necked flask. The atmosphere was replaced with nitrogen three times and the temperature was raised to 105°C for 16 h. After the reaction was completed, the mixture was cooled to room temperature and diluted with EA, filtered through celite, and 10 mL of water was added. The mixture was extracted with ethyl acetate (20 ml*3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and the filtrate was filtered and passed through a column to obtain T28-3 (2.3 g, light yellow solid).

[0248] 1 H NMR(400MHz,Chloroform-d)δ8.46(d,J=2.4Hz,1H),7.51(d,J=8.1Hz,2H),7.41(d,J=2.5Hz,1H),7 .25(d,J=8.1Hz,3H),5.51(s,1H),4.18(s,2H),3.99(s,2H),3.55(s,2H),2.22(s,2H),1.50(s,9H).

[0249] (3) Synthesis of T28-4

[0250] T28-4 (200 mg, 0.4423 mmol, 1.0 eq), boronate (230.1 mg, 1.11 mmol, 2.5 eq), NaHCO3 (167.2 mg, 1.99 mmol, 4.5 eq), Pd(OAC)2 (10 mg, 0.044 mmol, 0.1 eq), and PCy3 (25 mg, 0.088 mmol, 0.2 eq) were added to a reaction flask. The solvent was added with 1,4-dioxane / EtOH / water (7:2:1) (1.4 ml / 0.4 ml / 0.2 ml). After nitrogen was replaced three times, the mixture was placed in an oil bath and heated to 105 degrees for 12 hours. After the reaction was completed and cooled to room temperature, 10 mL of water was added and extracted with ethyl acetate (10 ml*3). The combined organic layers were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, filtered, and then passed through a column to obtain the product T28-4 (122 mg).

[0251] 1 H NMR(400MHz,Chloroform-d)δ8.86(d,J=2.2Hz,1H),7.85(d,J=2.2Hz,1H),7.50(d,J=8.0Hz,2H),7.42(d,J=2.3Hz,1H),7.31 -7.24(m,2H),6.57(d,J=2.3Hz,1H),5.53(d,J=29.2Hz,1H),4.24(s,2H),3.97(s,5H),3.55(s,2H),2.27(s,2H),1.51(s,9H).

[0252] (4) Synthesis of T28-5

[0253] T28-4 (1 g) was dissolved in ethanol (10 mL), and triphenylphosphine rhodium chloride (200 mg, 20%) was added. The mixture was reacted under high-pressure hydrogen for 24 h. If the raw material was not completely reacted, 0.9 g of T26-5 (white solid) was obtained after column chromatography.

[0254] (5) Synthesis of Compound T28-6

[0255] Compound 5 (0.9 g) was added to DCM (8 ml), followed by the addition of HCl / dioxane (20 mL, 4 M), and the mixture was reacted overnight at room temperature. 800 mg of T28-6 was obtained after direct spin drying.

[0256] (6) Synthesis of Compound T28

[0257] Compound T28-6 (800 mg, 2.03 mmol, 1.0 eq), triethylamine (615.1 mg, 6.09 mmol, 3.0 eq), and DCM (8 ml) were added to a reaction flask. A solution of acryloyl chloride (202.11 mg, 2.33 mmol, 1.1 eq) in DCM (6 ml) was then added dropwise at zero temperature and stirred overnight at room temperature. The solution was washed with 0.1 N HCl and extracted with EA. The product was then purified by column chromatography using petroleum ether and EA to obtain 100 mg of T28 as a white solid. LC-MS [M+1]: 455.2

[0258] Referring to the synthesis method of compound T28, the following compounds were synthesized:

[0259] Biological activity test experiment

[0260] Experimental Example 1 Cell Anti-Proliferation Experiment

[0261] Proliferation inhibition assay of YAP-TEAD inhibitor compounds on lung squamous cell carcinoma cell line NCI-H226

[0262] Experimental Materials and Equipment: Lung squamous cell carcinoma cells NCI-H226 were purchased from Nanjing Kebai Biotechnology Co., Ltd. RPMI-1640 medium (Bio-Channel), DMSO (dimethyl sulfoxide), CCK8 (WST-8) cell analysis kit (Biyuntian), 0.25% EDTA-Tripsin (trypsin digestion solution), 1x PBS (phosphate buffered saline, pH 7.2), 96-well plates (Corning), fetal bovine serum (FBS), 10,000 U / mL penicillin-G / streptomycin, a high-speed refrigerated centrifuge (EPPENDORF 5810R), and an enzyme-linked immunosorbent assay (Tecan Spark).

[0263] Experimental preparation:

[0264] 1. Cell plating

[0265] A) Tumor cells were cultured at 37°C and 5% CO 2 The cells were cultured in RPMI-1640 (containing 10% FBS and 100 U / mL penicillin-G / streptomycin) under conditions of saturated humidity to 80-90% confluence.

[0266] B) Remove the culture medium from the 10 cm culture dish;

[0267] C) Rinse the cells once with 10 ml of 1x PBS;

[0268] D) Add 4 ml of 0.25% EDTA-Tripsin and place in a 37°C, 5% CO 2 Trypsinize in an incubator for 5 minutes, transfer to a 15 ml centrifuge tube, centrifuge at 200 g for 5 minutes, and discard the supernatant to obtain a cell pellet;

[0269] E) Resuspend in 4 ml of DMEM medium, count and adjust to 10,000 cells / ml.

[0270] F) Add the cell suspension to each well of a 96-well plate at a volume of 100 μL and incubate at 37°C with 5% CO 2 Culture in an incubator overnight.

[0271] 2. Compound treatment

[0272] Compound dilution

[0273] A) Prepare test compound serial dilutions: Prepare a 1 mM stock solution of the test compound. Dissolve 1.5 μl of the stock solution in 1.5 ml of DMSO-free culture medium. Perform a 3-fold serial dilution in 0.1% DMSO culture medium for a total of 9 concentrations. The compound concentrations after dilution are as follows:

[0274] 333.33nM, 111.11nM, 37.03nM, 12.35nM, 4.15nM, 1.37nM, 0.46nM, 0.15nM

[0275] B) After thorough mixing, 100 μL of the culture compound solution was taken to replace the culture medium in the cell culture plate, with 4 replicates per concentration;

[0276] C) The cells were transferred to an incubator and incubated for 3 days.

[0277] 3. CCK8 (WST-8) cell analysis

[0278] A) Remove the cell culture plate and add 10 μl of CCK-8 (WST-8) solution to each well in a biosafety cabinet.

[0279] B) Return the cell culture plate to the incubator and continue incubating for 3 hours;

[0280] C) The absorbance value was measured on a TECAN enzyme-linked immunosorbent assay (ELISA) at a wavelength of 450 nm.

[0281] 4. Data Analysis

[0282] The cell viability (%Cell Viability) was calculated using the following formula: Cell viability (%) = [A(drug added) - A(blank)] / [A(0 drug added) - A(blank)] × 100

[0283] A(drug added): absorbance of the wells containing cells, CCK8 solution, and drug solution

[0284] A (blank): absorbance of the well with culture medium and CCK8 solution but no cells

[0285] A(0 drug addition): absorbance of the well containing cells, CCK8 solution but no drug solution

[0286] Cell viability: Cell proliferation activity or cytotoxicity activity was obtained by curve fitting using GraphPad Prism 8 software. 50 Numeric value.

[0287] Experimental Example 2: Detection of YAP-TEAD Inhibitor Activity Using Nano Luciferase Method

[0288] (1) Experimental materials and equipment: HEK 293T cells (human embryonic kidney cells) were purchased from Nanjing Kebai Biotechnology Co., Ltd. DMEM medium (high glucose, phenol red-free, Bio-Channel), DMSO (dimethyl sulfoxide), Lipo6000 TM Transfection reagent (Biyuntian), pGL3B-8xGTiiC-nLuc-CMV-fLuc plasmid, 0.25% EDTA-Tripsin (trypsin digestion solution), 1xPBS (phosphate buffered saline, pH 7.2), 96-well white cell culture plates (PerkinElmer), fetal bovine serum (FBS), 10,000 U / mL penicillin-G / streptomycin, high-speed refrigerated centrifuge (EPPENDORF 5810R), 37°C CO 2 incubator, Cell counter, Envision microplate reader (PerkinElmer).

[0289] Reagents

[0290] Reagent Catalog number Concentration

[0291] Nano-luciferase Assay Reagent MES pH 6.0 69892-25G 100mM

[0292] CDTA CAS:125572-95-4 1mM

[0293] Tergitol NP10-100ML 0.5%(v / v)

[0294] Mazu DF 204A8311-50ML 0.05% (v / v)

[0295] KCl CAS:7447-40-7 150mM

[0296] DTT Roche 10197777001 1mM

[0297] thiourea T8656-50G 35mM

[0298] Furimazine 1374040-24-0 20μM Add before use

[0299] (2) Transient transfection of 293T cells

[0300] The revived 293T cells were seeded into a 10 cm culture dish and placed in a 5% CO 2 Culture in an incubator at a constant temperature of 37°C. To ensure transfection efficiency, cells in the logarithmic phase (cell density of approximately 50%-70%) should be used.

[0301] One day before transfection, cells in the logarithmic phase were digested with Trypsin-EDTA, the reaction was terminated by adding culture medium, and the cells were mixed by pipetting to prepare a cell suspension.

[0302] Use Vi-cell to determine the cell concentration and dilute to a suspension of 5*10^5 cells per ml. After the cell suspension is prepared, gently mix it and add 10 ml of liquid to a 10 cm culture dish. In this way, the number of cells in each 10 cm culture dish is 5*10^6. 2 Culture in an incubator at 37°C for 1 day.

[0303] Take two clean, sterile centrifuge tubes and add 750μL of antibiotic- and serum-free Opti-MEM Medium to each. Add 15μg of plasmid (pGL3B-8xGTiiC-nLuc-CMV-fLuc) to one tube and mix thoroughly by pipetting gently. Add Lipo6000 transfection reagent to the other tube and mix thoroughly by pipetting gently. After standing at room temperature for 5 minutes, gently add the culture medium containing DNA to the culture medium containing Lipo6000 transfection reagent. Gently invert the tube to mix thoroughly. Let stand at room temperature for 5 minutes.

[0304] The above mixture was evenly added dropwise to a 10 cm culture dish and replaced with fresh complete culture medium after culturing for 6 hours.

[0305] (3) 96-well plate plating

[0306] One day after transfection, the cells were digested with Trypsin EDTA, the reaction was terminated by adding culture medium, and the cells were mixed by pipetting to prepare a cell suspension.

[0307] The cell concentration was determined using Vi-cell and diluted to a suspension of 20,000 cells per ml.

[0308] After the cell suspension is prepared, mix gently and add 100 μL to each well of a 96-well plate so that the density of the cells to be tested is 2000 per well.

[0309] (4) Adding compound

[0310] The inoculated cell culture plate was placed in an incubator for culture, and compounds with gradient concentrations were added after about 24 hours.

[0311] 10 mM compound stock solution was diluted to 50 μM with culture medium, and 50 μM compound solution was added to the third column of the deep-well plate, and 216 μL of culture medium containing 0.5% DMSO was added to the fourth to eleventh columns.

[0312] Gradient dilution: Pipette 100 μL of solution from the third column and add it to the fourth column. Mix well. Then pipette 100 μL of solution from the fourth column and add it to the fifth column. Repeat this operation until the eleventh column.

[0313] Using a multichannel pipette, 25 μL of compound solution was pipetted from the deep-well plate into a 96-well culture plate. Each compound was plated four times on the 96-well plate. Finally, a concentration gradient of 1:3.16 was formed with a maximum concentration of 10,000 nM on the 96-well plate.

[0314] (5) Add Nano-luciferase detection reagent and read the results

[0315] 96-well plates were heated in 5% CO 2 After culturing at 37°C in an incubator for 48 hours, the cells were taken out and equilibrated at room temperature for 10 minutes.

[0316] Add 100 μL of detection reagent to each well and shake at low speed on a horizontal shaker for 10 minutes to fully lyse the cells. Measure the fluorescence value of each well using a PerkinElmer Envision microplate reader.

[0317] (6) Calculation of results

[0318] Using 0 nM as the control, the values ​​of each well were converted into percentages, and the IC was calculated by nonlinear fitting using [Inhibitor] vs. response (three parameters) in GraphPad Prism software. 50 .

[0319] As shown in Table 1, where A≤100nM; 100nM <B<1μM;5μM≥C≥1μM。

[0320] Table 1 "ND" means not detected.

[0321] Experimental Example 3 Pharmacokinetic Study of Drugs

[0322] Oral administration solvent: 5% DMSO + 10% Solutol HS15 + 85% normal saline

[0323] Preparation process for oral administration: Weigh an appropriate amount of T18 powder, add an appropriate volume of DMSO, vortex, add an appropriate volume of Solutol solution, vortex, add an appropriate amount of physiological saline, vortex and sonicate to a uniform and clear preparation solution.

[0324] For clear solution preparation, keep 2 samples, 100 μL / sample, and store at 2-8°C

[0325] The animal room was equipped with an air-conditioning system and good ventilation. The indoor temperature was maintained between 20 and 26°C, and the humidity was maintained between 40% and 70%. Artificial lighting was used in the animal room, with a 12-hour light and dark cycle (except when working lighting was required for experimental operations or cleaning). Experimental animals had free access to food and water.

[0326] Animals were fed normally for at least 3 days after purchase. Rats that met veterinary standards were enrolled in this study and were labeled with a tail number. Animals in the oral administration group were fasted overnight before dosing and resumed feeding 4 hours after dosing, with free access to water.

[0327] Animal grouping and dosing Note: 1) Animals were allowed to drink water freely before and after administration; 2) All experiments were conducted according to the actual body weight of the animals.

[0328] Before administration, check the state of the dosage formulation and ensure the uniformity of the formulation by vortexing, stirring or shaking. Calculate the theoretical dosage volume for each SD rat in each group according to the following formula.

[0329] Administration: Rats were orally administered and fasted overnight before administration.

[0330] Sample collection information Note: The blood collection time window for blood collection points within 1 hour (excluding the blood collection point before administration) is ±1 minute, and the blood collection time window for other time points is ±5%; the samples are sent for testing.

[0331] Table 3

[0332] Experimental Example 4: Thermal Shift Assay of Tead Protein Inhibitor T18

[0333] (1) Experimental materials and equipment: Protein Thermal Shift Dye Kit, 384-well clear plate、MicroAmp TM Optical Adhesive Film was purchased from Thermo Fisher Scientific, Multiplate TM 96-well, clear PCR plates were purchased from BIO-RAD. Human TEAD1 was purchased from Sinobiological, and Human TEAD2, Human TEAD3, and Human TEAD4 were purchased from WuXi AppTec (high glucose, phenol red-free, Bio-Channel). DMSO (dimethyl sulfoxide) was used for experimental testing using a Real-Time PCR System. Protein thermal shift dye was used at 40X. 1 μg of protein was used for each assay.

[0334] Test temperature range: 25℃-99℃.

[0335] (2) Thermal migration experimental methods and processes

[0336] Four secondary pore experiments were performed for the reaction.

[0337] The in vitro protein thermal shift assay conditions for human recombinant proteins TEAD1, TEAD2, TEAD3, and TEAD4 were set up as follows:

[0338] a. TEAD protein amount per reaction: 1 μg

[0339] b. Compound T18 concentration: 12.5 μM

[0340] 2.1 Thermal shift assay of TEADs proteins

[0341] 1) Dilute protein thermal shift dye (1000X) to 40X and use immediately.

[0342] 2) Place the appropriate reaction plate on ice and prepare the protein melt curve reaction.

[0343] Reaction system per well:

[0344] 3) Pipette each reaction mixture up and down 10 times to mix thoroughly.

[0345] 4) Use The plate was sealed with optical adhesive film, centrifuged at 1000 rpm for 1 min, and then placed on ice.

[0346] 5) Transfer the prepared plate to QuantStudio TM 7Flex, and set up the experiment as follows.

[0347] a. Experimental setup:

[0348] Instrument Type: QuantStudio TM 7Flex system; Module: 384-well; Experiment type: Melting curve; Reagents: Other;

[0349] Run the instrument as Fast; define Target: Reporter-ROX; Quencher-None; and set Reference Fluorescence to None.

[0350] Allocate plates according to experimental design.

[0351] b. Operation method:

[0352] Reaction volume per well: 10 μL; Reaction steps: Step 1: 25°C for 2 min, Step 2: 1.6°C / s, 99°C for 2 min; Filter selection: x1-m3

[0353] c. Start the run and save the .EDS file.

[0354] 6) Protein Thermal Shift TM Software to analyze data.

[0355] 2.2 Data Analysis

[0356] Protein Thermal Shift TM The software analyzes the resulting EDS file, derives the melting temperature (Tm) from the melting curve, calculates the migration shift of Tm, and simultaneously exports fluorescence and derivative plots.

[0357] 3. Results

[0358] The Tm changes of T18 for human TEAD1, TEAD2, TEAD3, and TEAD4 proteins are shown in Figure 1, Table 4, and Table 5.

[0359] Table 4: Tm values ​​of human TEAD protein alone or in the presence of T18

[0360] Table 5: ΔTm values ​​of human TEAD protein alone or in the presence of T18

[0361] 4. Summary and Discussion

[0362] Under these experimental conditions, T18 changed the Tm values ​​of all four TEAD family members compared with DMSO, but a greater effect was observed on TEAD1, indicating that T18 is a selective inhibitor of TEAD1 protein.

[0363] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.

Claims

1. A compound of formula I or a pharmaceutically acceptable salt, solvate or prodrug thereof, in, X1, X2, X3, and X4 are each independently selected from the following group: CR, N; R is independently selected from the group consisting of H, halogen, CN, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, aryl, heteroaryl; A is selected from the following group: B is selected from the following group: L is selected from the group consisting of NR4, O, S, Se, sulfoxide, sulfone, CR2R3; R1 is selected from the group consisting of H, CF3, CF2H, methyl, ethyl, isopropyl, cyclopropyl, trifluoromethoxy, SF5, tert-butyl; R2 is independently selected from the following group: H, halogen, CN, NH2, hydroxyl, ester group, urea group, carbamate group, amide group, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, aryl, heteroaryl, among which NH2, ester, urea, carbamate, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 The hydrogen in the cycloalkoxy, aryl and heteroaryl groups can be arbitrarily substituted, and the substituents are halogen, CN, NH2, hydroxyl, ester, urea, carbamate, amide, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, C 3-6 Cycloalkoxy, aryl, heteroaryl, or R2 and the structure to which it is connected form a 3-7 membered ring, or different R2s form a 3-7 membered ring; R3, R4, and R5 are each independently selected from the group consisting of H, F, methyl, and CN; m is each independently selected from the following group: 0, 1, 2, 3, 4, 5, 6.

2. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof, characterized in that: m is selected from the following group: 0, 1, 2, 3.

3. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof, characterized in that: The compound is shown in Formula II, Formula III, or Formula IV: Wherein, X2, A, B, L, and R1 are as defined in claim 1.

4. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof, characterized in that: A is selected from the following group: B is selected from the following group: R2, R3, R4, R5 and m are as defined in claim 1.

5. The compound according to claim 1 or a pharmaceutically acceptable salt, solvate or prodrug thereof, characterized in that: B is selected from the following group: R2, R3, R4, R5 and m are as defined in claim 1.

6. A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, characterized in that: The compound is selected from the group consisting of:

7. A pharmaceutical composition, characterized in that It comprises a pharmaceutically acceptable carrier and one or more safe and effective amounts of the compound according to claim 1 or 6 or a pharmaceutically acceptable salt, solvate or prodrug thereof.

8. Use of the pharmaceutical composition according to claim 7, characterized in that: Used for preparing a medicament for preventing and / or treating a proliferative disease.

9. Use of the pharmaceutical composition according to claim 7, characterized in that: For use in the preparation of a medicament for use selected from the group consisting of: 1) Prevent and / or treat diseases caused by abnormal activity of YAP / TEAD; 2) Prevent and / or treat diseases caused by Hippo pathway dysregulation; 3) Prevent and / or treat diseases related to YAP or TAZ or YAP / TAZ or TEAD or YAP / TEAD or YAP / TAZ / TEAD dysregulation.

10. A combination of a compound according to claim 1 or 6 or a pharmaceutically acceptable salt, solvate or prodrug thereof and a second drug, characterized in that: For the prevention and / or treatment of cancer; The second drug is selected from the group consisting of ERK inhibitors, MEK inhibitors, KRAS inhibitors, BRAF inhibitors, EGFR inhibitors, Wnt inhibitors, and PD-1 inhibitors.

Citation Information

Patent Citations

  • Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity

    CN103814016A

  • Miazines BTK inhibitor, preparation method and medical application thereof

    CN104844573A

  • Heterocyclic compounds for TEAD inhibitors

    CN115466243A

  • Polycyclic compound and application thereof

    CN116425757A

  • Phenoxy-pyridyl derivatives

    WO2009081259A1